Hoth Therapeutics, Inc.HOTHEarnings & Financial Report
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on researching and developing targeted, novel therapies for unmet medical needs across dermatology, autoimmune diseases, and oncology indications. It primarily operates in the U.S. market, advancing multiple pipeline candidates aimed at improving patient outcomes for conditions with limited existing treatment options.
HOTH Q3 FY2024 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-2.2M
Net Profit
$-2.2M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.32
Hoth Therapeutics, Inc. Q3 FY2024 Financial Summary
Hoth Therapeutics, Inc. reported revenue of $0 for Q3 FY2024, with a net profit of $-2.2M (down 2.4% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-2.2M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2024 |
Hoth Therapeutics, Inc. Quarterly Revenue & Net Profit History
Hoth Therapeutics, Inc. results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2024 | $0 | — | $-2.2M | N/A |
| Q1 FY2024 | $1.2B | — | $-2.1M | -0.2% |
Income Statement
| Q1 2024 | Q3 2024 | |
|---|---|---|
| Revenue | $1.24B | $0 |
| YoY Growth | N/A | N/A |
Balance Sheet
| Q1 2024 | Q3 2024 | |
|---|---|---|
| Assets | $9.1M | $8.7M |
| Liabilities | $658735 | $813033 |
| Equity | $8.4M | $7.9M |
Cash Flow
| Q1 2024 | Q3 2024 | |
|---|---|---|
| Operating CF | $-1.7M | $-1.6M |